These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37596779)

  • 1. JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
    Tokareva K; Reid P; Yang V; Liew D; Peterson AC; Baraff A; Giles J; Singh N
    Expert Rev Clin Immunol; 2023; 19(11):1385-1397. PubMed ID: 37596779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
    Singh JA
    BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
    Atzeni F; Popa CD; Nucera V; Nurmohamed MT
    Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Start RA treatment - Biologics or JAK-inhibitors?
    Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
    Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
    Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
    Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
    Palominos PE; Lineburger IB; Xavier RM
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
    Russell MD; Stovin C; Alveyn E; Adeyemi O; Chan CKD; Patel V; Adas MA; Atzeni F; Ng KKH; Rutherford AI; Norton S; Cope AP; Galloway JB
    Ann Rheum Dis; 2023 Aug; 82(8):1059-1067. PubMed ID: 37247942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
    Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Cho SK; Kim H; Song YJ; Kim HW; Nam E; Lee SS; Lee HS; Park SH; Lee YA; Park MC; Chang SH; Kim HA; Kwok SK; Kim HR; Kim HS; Yoon BY; Uhm WS; Kim YG; Kim JH; Lee J; Choi J; Sung YK
    Korean J Intern Med; 2023 Jul; 38(4):546-556. PubMed ID: 37334513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.
    Liu L; Yan YD; Shi FH; Lin HW; Gu ZC; Li J
    Front Immunol; 2022; 13():977265. PubMed ID: 36248913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].
    Fiehn C
    Dtsch Med Wochenschr; 2024 Mar; 149(6):326-330. PubMed ID: 38412990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
    Alduraibi FK; Singh JA
    Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.